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Abstract
Background: Sapphyrin analogues and related porphyrin-like species have attracted attention as anticancer agents due to
their selective localization in various cancers, including hematologic malignancies, relative to surrounding tissues.
Sapphyrins are electron affinic compounds that generate high yields of singlet oxygen formation. Although initially explored
in the context of photodynamic therapy, sapphyrins have intrinsic anticancer activity that is independent of their
photosensitizing properties. However, the mechanisms for their anticancer activity have not been fully elucidated.
Results: We have prepared a series of hydrophilic sapphyrins and evaluated their effect on proliferation, uptake, and cell
death in adherent human lung (A549) and prostate (PC3) cancer cell lines and in an A549 xenograft tumor model. PCI-
2050, the sapphyrin derivative with the highest in vitro growth inhibitory activity, significantly lowered 5-bromo-2'-
deoxyuridine incorporation in S-phase A549 cells by 60% within eight hours and increased levels of reactive oxygen species
within four hours. The growth inhibition pattern of PCI-2050 in the National Cancer Institute 60 cell line screen correlated
most closely using the COMPARE algorithm with known transcriptional or translational inhibitors. Gene expression
analyses conducted on A549 plateau phase cultures treated with PCI-2050 uncovered wide-spread decreases in mRNA
levels, which especially affected short-lived transcripts. Intriguingly, PCI-2050 increased the levels of transcripts involved in
RNA processing and trafficking, transcriptional regulation, and chromatin remodeling. We propose that these changes
reflect the activation of cellular processes aimed at countering the observed wide-spread reductions in transcript levels. In
our A549 xenograft model, the two lead compounds, PCI-2050 and PCI-2022, showed similar tumor distributions despite
differences in plasma and kidney level profiles. This provides a possible explanation for the better tolerance of PCI-2022
relative to PCI-2050.
Conclusion: Hydrophilic sapphyrins were found to display promise as novel agents that localize to tumors, generate
oxidative stress, and inhibit gene expression.
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Background
Sapphyrins are a class of expanded porphyrins that were
first discovered as an unanticipated product during the
synthesis of vitamin B12 [1]. Subsequently, efficient
chemical synthesis of these compounds [2,3] led to the
discovery that sapphyrins can function as highly effective
anion binding receptors [4]. Sapphyrins possess a 22 π-
electron aromatic conjugation pathway and as a conse-
quence are more electron affinic than the corresponding
18 π-electron porphyrin systems [5]. Due to a relatively
high yield of singlet oxygen formation and near infrared
absorbance properties, their potential as therapeutic
agents was initially explored in the context of photody-
namic therapy [6,7]. In the course of these studies, it was
determined that sapphyrins can selectively accumulate in
tumors, relative to surrounding tissues, similar to porphy-
rins and other expanded porphyrin systems such as the
texaphyrins [8]. It was also noted that sapphyrins could
display a significant degree of inhibitory activity in cellu-
lar assays even in the absence of light [9]. Recently, we
reported the anti-cancer activity of several sapphyrin
derivatives in hematologic cell lines and tumors, confirm-
ing that sapphyrins possess intrinsic anticancer activity
that is independent of their photosensitizing properties
[10,11].
In this report, we describe the preparation of a series of
hydrophilic sapphyrin derivatives and the results of their
evaluation as anti-cancer agents in adherent cell lines and
a xenograft tumor model. We find that sapphyrin treat-
ment leads to an increase in intracellular reactive oxygen
species (ROS) and inhibits cell proliferation at early times,
leading to cell death upon more prolonged treatment.
Moreover, we have characterized gene expression profiles
of human lung cancer cells cultured in the presence of the
most active derivative in order to improve our under-
standing of the mechanism of action of these compounds.
Sapphyrin-treated cells showed a wide-spread inhibition
of gene expression, with short lived mRNAs displaying the
most prominent decreases. These data lead us to suggest
that sapphyrins act as global inhibitors of gene expression
and that this plays a major role in their anti-cancer activ-
ity.
Results
Chemical synthesis of hydrophilic sapphyrins
Hydrophilic sapphyrin derivatives were prepared by con-
densation of a dihydroxylated sapphyrin precursor [3]
with the corresponding tri(ethyleneglycol)methyl ether
(PEG) or hydroxyl substituted amines using an active car-
bonate method (Fig. 1A and Additional File 1). The purity
of all products was >90% as determined by reversed phase
HPLC analysis. Sapphyrins were formulated for biological
studies in 5% aqueous mannitol and quantified in meth-
anol using the extinction coefficient determined for the
parent compound (443 ε = 598,782 M-1 cm-1).
Antiproliferative activity of hydrophilic sapphyrins
The hydrophilic sapphyrins considered in this study all
displayed antiproliferative activity in A549 cells with a
50% growth inhibitory concentration (GI50) between ca.
0.5 and 2.5 µM measured 3 days after a 24 hour treatment
with the exception of PCI-2042 which was essentially
inactive (Fig. 1B). The order of compound activity was
PCI-2050 > PCI-2012 > PCI-2022 > PCI-2042. Similar
activity was observed in PC3 cells (Fig. 1C). Thus, antipro-
Effect of sapphyrins on cell proliferation Figure 1
Effect of sapphyrins on cell proliferation. A, Structure of sap-
phyrins. B, A549 and C, PC3 cancer cells were treated with 
inhibitors for 24 hours, medium was replaced, and relative 
proliferation measured after an additional 48 hours by tetra-
zolium salt reduction. The anti-proliferative activity of cispla-
tin is shown for comparison.
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liferative activity in cultured cells correlated inversely with
the number of hydroxyl group substituents. Treatment
with 2.5 µM sapphyrin PCI-2050 reduced BrdU incorpo-
ration in S-phase A549 cells by 60% within 8 hours (Fig.
2A).
Sapphyrin cell uptake and cytotoxicity
Cytotoxicity and uptake properties were examined in this
set of related sapphyrins (Fig. 2B–C). Treatment of A549
cells with 1.25 µM or 2.5 µM sapphyrin PCI-2050 led to
25% or 50% cell death, respectively, within 3 days as
measured using propidium iodide staining. A comparable
degree of cell death (40%) was obtained with 200 ng/mL
(0.16 µM) actinomycin D (data not shown). Other sap-
phyrins tested (PCI-2012, PCI-2022, and PCI-2042)
caused less cell death, with activity that correlated
inversely with the number of hydroxyl group substituents.
Uptake of sapphyrins into cells was estimated based on
their fluorescence in the near-infrared (>650 nm) channel
of the flow cytometer (Fig. 2C) [11]. Cell-associated sap-
phyrin fluorescence after four hours of exposure to the
four compounds correlated well with levels of cell death
after 72 hours. These data lead us to suggest that the anti-
proliferative and cytotoxic activities of sapphyrin conge-
Biological effects of sapphyrins on A549 lung cancer cells Figure 2
Biological effects of sapphyrins on A549 lung cancer cells. A, 5-Bromo-2'-deoxyuridine (BrdU) incorporation after exposure to 
PCI-2050 at indicated concentrations. The effect of actinomycin D (ActD, 200 ng/mL) treatment is shown for comparison. B, 
Cells were treated with inhibitors for 24 hours, medium was replaced, and viability measured after an additional 48 hours by 
propidium iodide staining. C, Cells were treated with sapphyrins for 4 hours, washed, and sapphyrin uptake estimated by cellu-
lar fluorescence above 650 nm. D, Cells were treated with PCI-2050 at indicated concentrations for 4 hours, washed, treated 
with dichlorofluorescin diacetate, and dichlorofluorescein fluorescence (DCF) measured in live-gated cells. Effect of hydrogen 
peroxide (H2O2, 200 µM), actinomycin D (Act D, 5 µg/mL), and pretreatment with L-buthionein- [S,R]-sulfoximine (BSO, 100 
µM) for 24 hours are shown for comparison.
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ners are largely determined by the rate of their cellular
uptake.
Formation of Reactive Oxygen Species (ROS) in A549 cells
The most active derivative, sapphyrin PCI-2050, was
selected for further mechanistic studies in vitro. A549 cells
treated with sapphyrin PCI-2050 displayed a dose-
dependent increase of intracellular peroxides (ROS) as
measured by the conversion of dichlorofluorescin acetate
(DCFA) to dichlorofluorescein (DCF) after four hours of
treatment (Fig. 2D) [12]. DCF signal following treatment
with 1.25 µM sapphyrin PCI-2050 was comparable to that
following treatment with 200 µM hydrogen peroxide. To
assess the involvement of the glutathione-dependent cel-
lular antioxidant system, control cells were treated with L-
buthionein- [S,R]-sulfoximine (BSO) overnight prior to
sapphyrin treatment. BSO-treated cultures displayed a
five-fold increase in DCF signal as compared to back-
ground, whereas cultures treated with 2.5 µM sapphyrin
PCI-2050 and BSO showed a 43-fold increase as com-
pared to the threefold increase seen upon exposure to 2.5
µM of sapphyrin PCI-2050 in the absence of BSO. This
observation is interpreted in terms of treatment with sap-
phyrin PCI-2050 leading to ROS formation within 4
hours, an effect that is partially masked by glutathione-
dependent pathways. Treatment with 5 µg/mL actinomy-
cin D also led to ROS formation, although to a lesser
degree than sapphyrin PCI-2050 at similar (5 µM) con-
centration.
National cancer institute cell line screen
Testing of PCI-2050 in the NCI Developmental Therapeu-
tics Program tumor cell line panel revealed broad overall
activity with an overall Log 50% growth inhibition (Log
GI50) of -7.04 with a range of 2.34 (Additional File 1). The
COMPARE algorithm [13] was used to identify com-
pounds present in the NCI synthetic compound database
with GI50 values correlating most closely to those of PCI-
2050. The most similar compounds (NCI accession
number, Pearson correlation coefficient) obtained from
this analysis were deoxybouvardin (NSC 259969, 0.841),
bouvardin (NSC 259968, 0.809), S-3'-deacetyl-phyllan-
thoside (NSC 342443, 0.807), and olivomycin (NSC
38270, 0.797). Interestingly, these compounds all have
been shown to induce global inhibition of transcription
or translation in eukaryotic cells [14-16].
Gene expression in sapphyrin-treated A549 cells
Plateau phase A549 cells treated with 2.5 µM PCI-2050 for
four hours showed a global inhibition of gene expression
with 4.7-fold more transcripts significantly down-regu-
lated than were up-regulated in response to drug (801 ver-
sus 170). Experiments conducted with a lower (1.25 µM)
dosage of PCI-2050 provided similar results with a 1.9-
fold excess of down-regulated relative to up-regulated
transcripts being seen (2,221 versus 1,187). Nevertheless,
as can be inferred from the difference seen at 2.5 and 1.25
µM, the relative proportion of down-regulated transcripts
is sensitive to drug dosage. Interestingly, reportedly short-
lived transcripts (e.g. MYC, ZNF217, and PNRC1) [17]
displayed prominent decreases (>3.5-fold, Benjamini-
Hochberg corrected p < 0.01) in their levels in response to
both dosages of PCI-2050. Conversely, according to our
criteria, the levels of reportedly longer lived transcripts
[17], such as ATP6V1A, GNS, and EIF2S3, were not signif-
icantly affected by either of these treatments.
Based on the these observations, one would predict that
the expression profiles of plateau phase A549 cells treated
with appropriate dosages of PCI-2050 or the transcrip-
tion-inhibiting agent actinomycin D would be similar.
Here, treatment with 5 µg/ml actinomycin D resulted in a
23.0-fold enrichment for down-regulated relative to up-
regulated transcripts (2,281 versus 99, respectively). Inter-
estingly, 42.8% of the 971 transcripts significantly
changed by 2.5 µM PCI-2050 were also changed in the
same direction by actinomycin D (Additional File 2).
Conversely, 17.5% of the 2,380 transcripts significantly
changed by actinomycin D were changed in the same
direction by 2.5 µM PCI-2050 (Additional File 2).
Although the gene expression profiles of PCI-2050 and
actinomycin D treated cells both reflect wide-spread
decreases in mRNA levels, there were intriguing differ-
ences, as highlighted by hierarchical clustering analysis
(Fig. 3). For example, the expression profiles of PCI-2050
treated samples were more closely related to those of the
untreated controls than to actinomycin D treated samples.
These sample groupings were driven by the behavior of
distinct subsets of genes. For example, 94 transcripts were
up-regulated in response to 1.25 µM PCI-2050 but down-
regulated in response to 5 µg/ml actinomycin D (Addi-
tional File 3). In fact, 25 transcripts were down-regulated
by actinomycin D but up-regulated by both dosages of
PCI-2050 (Additional File 4).
Gene Ontology (GO) analyses were used to identify func-
tional relationships among the various groupings of tran-
scripts discussed above (Additional File 1). The 94
transcripts up-regulated (>1.5-fold, Benjamini-Hochberg
corrected p < 0.01) in response to 1.25 µM PCI-2050 but
down-regulated (>1.5-fold, Benjamini-Hochberg cor-
rected p < 0.01) in response to actinomycin D were of spe-
cial interest. These transcripts could provide insights into
cellular responses to PCI-2050 that are not the result of
general transcriptional inhibition. Virtually all the
enriched GO categories involved transcription, chromo-
some organization, or RNA processing and transport
(Additional File 1). Intriguingly, there were at least eight
genes with transcriptional repressor activity, at leastMolecular Cancer 2007, 6:9 http://www.molecular-cancer.com/content/6/1/9
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eleven known or suspected chromatin remodeling genes,
and eight known or suspected RNA processing and trans-
port genes (Table 1).
Gene Ontology (GO) analyses of the 156 transcripts that
were up-regulated in response to both dosages of PCI-
2050 (Additional File 2) also were performed to investi-
gate cellular responses to this sapphyrin. Intriguingly,
RNA processing and transport genes were enriched in this
group of transcripts (Additional File 1). These genes
include HNRPD (aka AUF1), CPSF6, SFRS4 (aka SRP75),
ZNF638  (aka  NP220),  PCF11,  RBPMS,  MSI2, IGF2BP1
(aka CRDBP), and RBM16. The induction of the putative
RNA processing protein CROP (cisplatin resistance-associ-
ated overexpressed protein) is especially interesting since
it is also over-expressed in response to the anti-cancer
agent cisplatin [18]. Overall, the consistent induction of
RNA processing and transport genes by both dosages of
PCI-2050 highlights their importance as either potential
survival responses or active cellular processes mediating
the widespread reduction in transcript levels. In either
case, the gene expression profiles indicate that PCI-2050
and actinomycin likely have different mechanisms of
action. However, further functional analyses will need to
be conducted in order to identify the molecular target(s)
of sapphyrins leading to this activity.
Single dose toxicity studies
Lethality following a single-dose intravenous injection of
sapphyrin congeners was observed at doses ranging from
approximately 20 µmol/kg for PCI-2012 to 75 µmol/kg
for sapphyrin PCI-2042 (Table 2). Interestingly, com-
pounds bearing an increasing number of hydroxyl group
substituents were progressively better tolerated, i.e., PCI-
2050 ~ PCI-2012 < PCI-2022 < PCI-2042.
Efficacy studies in a tumor xenograft model
Sapphyrins PCI-2050 (10 µmol/kg/day for 2 days) and
PCI-2022 (20 µmol/kg/day for 2 days) were administered
intravenously to A549 tumor-bearing mice (Fig. 4A). Sap-
phyrin doses were chosen in this case to be less than or
equal to half of the maximum tolerated dose as deter-
mined by single dose toxicity studies (Table 2). Tumor
growth inhibition was compared with that of cisplatin (4
mg/kg q.d. × 4 i.p.). Sapphyrin PCI-2050 and cisplatin
cohorts both appeared to inhibit A549 tumor growth rel-
ative to control, although neither cohort reached statisti-
cal significance (p > 0.05). Treatment with PCI-2022 at
the higher dose displayed a significant effect (p < 0.001).
Weight loss of mice following treatment was less than 5%
in all groups.
Pharmacokinetic studies
The biodistribution of sapphyrins PCI-2022 and PCI-
2050 in plasma, kidneys, and A549 tumor xenografts was
measured over the course of 48 hours following intrave-
nous co-administration of the compounds at a dose of 5
µmol/kg each (Fig. 4B). Plasma levels of PCI-2022 were
initially higher than those of PCI-2050, but lower after 24
and 48 hour time intervals. Conversely, the levels of PCI-
2050 in kidney were initially higher than those of PCI-
2022, but lower after 24 and 48 hour time intervals.
Tumor levels of both compounds were found to be similar
after all time intervals examined.
Discussion
Based on previous observations of the selective accumula-
tion of sapphyrins in tumors [8], and their potent antipro-
liferative and cytotoxic activities [10], a series of
Hierarchical clustering analysis of gene expression data from  drug-treated A549 cell cultures Figure 3
Hierarchical clustering analysis of gene expression data from 
drug-treated A549 cell cultures. The dendrograms were gen-
erated based on average linkage hierarchical clustering of 
expression data from 422 probe tilings whose coefficient of 
variation was greater than 0.15 across all groups. Data from 
untreated (mannitol) and drug-treated [(sapphyrin PCI-2050 
= 2050) or (actinomycin D = ActD)] A549 cultures are pro-
vided in triplicate using the noted concentrations. The rela-
tive expression levels (↑ = up-regulated, ↓ = down-
regulated) of selected gene groupings in drug-treated versus 
control cells are provided on the right side of the figure. 
Note that this reflects relationships only within the subset of 
genes used for cluster analysis.
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Table 1: Selected transcripts up-regulated by 1.25uM PCI-2050 but down-regulated by 5 ug/ml actinomycin D.
Type Probe Set Ida Gene Titleb Symbol GeneIDc FC PCI-2050d Pe FC ActDf Pe
Transcription
al Repressor 
Activity
221230_s_at AT rich interactive domain 4B ARID4B 51742 1.76 0.0067 -6.83 0.0024
231292_at E1A-like inhibitor of differentiation 3 EID3 493861 5.51 0.0006 -3.84 0.0096
203643_at Ets2 repressor factor ERF 2077 1.74 0.0014 -3.27 0.0023
202484_s_at methyl-CpG binding domain protein 2 MBD2 8932 1.50 0.0086 -1.62 0.0038
220746_s_at receptor associated protein 80 RAP80 51720 1.60 0.0025 -1.95 0.0026
218166_s_at remodeling and spacing factor 1 RSF1 51773 2.17 0.0028 -2.78 0.0040
219682_s_at T-box 3 (ulnar mammary syndrome) TBX3 6926 1.76 0.0043 -4.19 0.0014
214714_at zinc finger protein 394 ZNF394 84124 1.70 0.0033 -3.18 0.0012
Chromatin 
Remodelling
208445_s_at bromodomain adjacent to zinc finger 
domain, 1B
BAZ1B 9031 1.62 0.0017 -2.22 0.0015
208686_s_at bromodomain containing 2 BRD2 6046 2.35 0.0008 -4.10 0.0008
225026_at chromodomain helicase DNA binding 
protein 6
CHD6 84181 1.72 0.0039 -2.28 0.0064
225357_s_at INO80 complex homolog 1 (S. cerevisiae) INOC1 54617 1.95 0.0026 -2.48 0.0045
243003_at Myeloid/lymphoid leukemia; translocated to, 
10
MLLT10 8028 1.61 0.0032 -2.01 0.0100
1563321_s_at Myeloid/lymphoid leukemia; translocated to, 
10
MLLT10 8028 1.81 0.0071 -2.39 0.0046
201703_s_at protein phosphatase 1, regulatory subunit 10 PPP1R10 5514 1.81 0.0027 -3.88 0.0013
209486_at disrupter of silencing 10 SAS10 57050 2.02 0.0015 -5.61 0.0012
225655_at ubiquitin-like, with PHD & RING finger 
domains, 1
UHRF1 29128 1.56 0.0040 -1.63 0.0095
1554441_a_at wings apart-like homolog (Drosophila) WAPAL 23063 1.67 0.0037 -3.00 0.0029
212267_at wings apart-like homolog (Drosophila) WAPAL 23063 2.47 0.0017 -4.81 0.0033
RNA Binding 
and 
Processing
225694_at Cdc2-related kinase, arginine/serine-rich CRKRS 51755 1.51 0.0023 -2.96 0.0070
218092_s_at HIV-1 Rev binding protein HRB 3267 1.54 0.0074 -1.64 0.0070
223295_s_at LUC7-like (S. cerevisiae) LUC7L 55692 1.82 0.0020 -1.87 0.0032
203378_at PCF11, cleavage and polyadenylation factor 
subunit
PCF11 51585 2.36 0.0015 -3.89 0.0020
238122_at RNA binding motif protein 12B RBM12B 389677 2.75 0.0010 -2.61 0.0013
51228_at RNA binding motif protein 12B RBM12B 389677 1.81 0.0022 -2.63 0.0078
201586_s_at splicing factor proline/glutamine-rich SFPQ 6421 1.51 0.0044 -1.77 0.0020
217833_at synaptotagmin binding, cytoplasmic RNA 
interacting
SYNCRIP 10492 1.52 0.0083 -1.54 0.0096
203519_s_at UPF2 regulator of nonsense transcripts UPF2 26019 1.60 0.0059 -1.90 0.0080
aAffymetrix designation
bAbbreviated gene description
cNCBI GeneID designation
dFold change in response to 1.25uM PCI-2050
eBenjamini-Hochberg corrected Student's t-test
fFold change in response to 5ug/mL actinomycin DMolecular Cancer 2007, 6:9 http://www.molecular-cancer.com/content/6/1/9
Page 7 of 12
(page number not for citation purposes)
structurally related sapphyrins was prepared and analyzed
for biological activity in cell culture and xenograft model
systems [11]. Initial work comparing compounds differ-
ing in the identity of solubilizing substituents (ether vs.
hydroxyl) indicated that the former (PCI-2050) was supe-
rior to the hydroxylated congeners (PCI-2012, PCI-2022,
PCI-2042) in terms of antiproliferative effects (Fig. 1).
Further studies in vitro similarly revealed an inverse corre-
lation between cytotoxic activity (Fig. 2B) and the number
of hydroxyl group substituents present on the periphery of
the sapphyrin macrocycle. These properties, perhaps
unsurprisingly, were further correlated with the rate of cel-
lular uptake of these compounds (Fig. 2C). This finding
led us to conclude that the presence and identity of the
solubilizing groups were relatively unimportant in terms
of sapphyrin activity once the compounds penetrated the
subcellular compartment. Further mechanistic studies
were therefore conducted using PCI-2050, the derivative
which showed the highest in vitro activity and rate of cel-
lular uptake.
There is increasing appreciation that the induction of oxi-
dative stress contributes to the specific and non-specific
activities of a variety of anticancer agents such as bleomy-
cin and adriamycin [19,20]. Here, we found dose-depend-
ent formation of reactive oxygen species (ROS) occurred
as an early event in A549 cells treated with PCI-2050 (Fig.
2D). The formation of ROS is consistent with the relative
ease of reduction of this expanded porphyrin [5], which
could lead to redox cycling under biological conditions.
This effect appeared at a similar time and concentration
required to inhibit 5-bromo-2'-deoxyuridine incorpora-
tion and cellular proliferation (Fig. 2A), prior to cell
death. Treatment with actinomycin D (5 µg/mL = 4 µM)
also led to an increase of ROS (2.3-fold), although not to
the same degree as the corresponding molar equivalent of
PCI-2050. In terms of potency, sapphyrin activity
appeared similar to and in some cases (e.g., PCI-2050)
superior to that of cisplatin, but lower than that of actino-
mycin D (Cf., Figs. 1 and 2A).
In an effort to gain a more detailed understanding of the
mechanistic basis for its anticancer activity, we studied the
effect of PCI-2050 on gene expression profiles in plateau
phase A549 cells. We selected plateau phase cultures in
order to focus on expression changes occurring in
response to treatment with drug that are not effected by
cell cycle occupancy. In preliminary studies, we observed
widespread decreases in transcript levels within four
hours of exposure to two different dosages of PCI-2050. In
a global sense, this mimicked cellular responses to actino-
Activity of sapphyrins in A549 tumor xenograft model Figure 4
Activity of sapphyrins in A549 tumor xenograft model. A, 
Median tumor volume (± SEM) over time in mice treated 
with control (5% mannitol) vehicle, cisplatin (4 mg/kg q.d. × 4 
i.p.), PCI-2050 (10 µmol/kg qd × 2 i.v.), or PCI-2022 (20 
µmol/kg qd × 2 i.v.). * p < 0.001. B, Log concentration of PCI-
2022 and PCI-2050 in plasma (µM) or in kidney and tumor 
(nmol/g) over time is shown.
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Table 2: Single-dose toxicity in CD1 mice.
Compound Dose (µmol/kg) Observed Lethality
PCI-2012 20 1/3
30 0/3
40 3/3
PCI-2022 30 0/3
40 0/3
60 3/3
PCI-2050 20 0/3
25 0/3
30 3/3
PCI-2042 50 1/3
60 0/3
75 2/3Molecular Cancer 2007, 6:9 http://www.molecular-cancer.com/content/6/1/9
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mycin D, a well-characterized transcriptional inhibitor.
However, several striking differences in gene expression
profiles (Fig. 3, Table 1) between these two anti-cancer
agents highlight the fact that they likely promote wide-
spread transcript decreases by unrelated mechanisms. For
example, the induction of transcription factors with
known repressor activities, chromatin remodeling genes,
and RNA processing and transport transcripts by the lower
dose of PCI-2050 contrasts their down-regulation in
response to actinomycin D (Table 1). RNA processing and
transport transcripts were up-regulated in response to
both dosages of PCI-2050 (Additional Files 1 and 2). We
propose that the induction of these transcripts serve as
survival responses aimed at countering the effects of drug-
induced transcript decreases. This information provides
insights into biochemical pathways which regulate cellu-
lar transcriptional activity on a global-scale.
The widespread decreases in transcript levels due to PCI-
2050 observed by microarray are consistent with the
results of COMPARE analysis of antiproliferative activity
in the NCI 60 tumor line panel, which includes PC3 cells,
indicating a similarity to anticancer agents known to
inhibit RNA transcription or protein synthesis. The COM-
PARE algorithm does not appear to distinguish between
compounds targeting these two processes [14]. Overall,
the mechanisms of other agents that produce wide-spread
decreases in transcript levels such as actinomycin D, 5,6-
dichloro-1-h-ribofuranosylbenzimidazole (DRB), fla-
vopiridol, 4-amino-6-hydrazino-7-beta-D-ribofuranosyl-
7H-pyrrolo(2,3-d)-pyrimidine-5-carboxamide (ARC),
and α-amanatin are quite varied. For example, actinomy-
cin D is thought to inhibit transcription initiation by
intercalating into DNA [21]. In contrast, DRB, flavopiri-
dol, and ARC inhibit transcription elongation by affecting
the activity of factor P-TEFb, a complex of cyclins with
CDK9 [22,23]. Meanwhile, α-amanitin directly inhibits
both transcriptional initiation and elongation by binding
directly to RNA polymerase II [24]. In addition, the topoi-
somerase inhibitor camptothecin has also been reported
to affect wide-spread reductions in transcript levels in cul-
tured cancer cells [25]. Thus, multiple nucleic acid meta-
bolic pathways can be targeted to yield wide-spread
decreases in transcript levels. Although it could prove
challenging to identify the specific molecular mechanism
mediating sapphyrin activity, there are several powerful
experimental approaches to address this issue. For exam-
ple, nuclear run-on assays and immunoblot analyses of
phospho-RNA polymerase II levels have proven valuable
for the dissecting the molecular basis for ARC activity
[22,23]. In addition, the affinity of sapphyrin for DNA,
RNA, and various proteins, especially those involved in
nucleic acid structure and function, can be tested by affin-
ity chromatography or surface plasmon resonance (SPR)
based techniques. Furthermore, it is possible that genetic
screens for sapphyrin-resistance in model organisms (e.g.
yeast) could shed light on its molecular targets.
Although the precise molecular target for their effects
remains undefined, the identification of sapphyrins as
general transcriptional inhibitor, based on COMPARE
analysis of the NCI 60 tumor line panel and A549 gene
expression profiling experiments, provides a plausible
mechanism for their anticancer activity. Inhibition of
gene expression can effectively squelch transcriptional
responses to stresses and compromise cellular survival
responses. For example, batteries of survival genes down-
stream of the transcription factors MTF-1, HIF-1, and
NRF-2 previously shown to be induced in A549 cells
under oxidative stress were not differentially expressed in
response to PCI-2050 or actinomycin D, despite ROS
accumulation [26,27]. Additional in vitro studies are
required to determine whether transcriptional inhibition
is causally related to the formation of ROS, and, if so, to
delineate the pathways involved. It is also important to
conduct similar studies in vivo to confirm that conclusions
derived from cultured cancer cells are valid in whole
organisms.
PCI-2050 was previously shown to display significant
antitumor activity in Ramos B-cell lymphoma and RKO
colon cancer xenograft models [11]. In this study, we
explored the effect of different solubilizing substituents
on in vitro activity and compared two compounds in a
somewhat more resistant A549 lung cancer xenograft
model. Although PCI-2050 displayed the highest biologi-
cal activity in vitro, compounds substituted with multiple
hydroxyl groups, such as sapphyrin PCI-2022, appeared
to be better tolerated (Table 2), and may therefore offer
improved therapeutic potential. For example, comparison
of PCI-2050 and PCI-2022, administered at similarly
well-tolerated doses (10 or 20 µmol/kg, respectively, for
two days), indicated that a significant benefit (p < 0.001)
could be obtained using the higher dose of the better-tol-
erated compound (Fig. 4A).
To assess whether pharmacokinetic properties could
account for these differences, the biodistributions of PCI-
2050 and PCI-2022 in plasma, kidney, and tumor were
compared by administering equimolar amounts of these
compounds in a single-dose injection. Although it is pos-
sible that drug-drug interactions might interfere with the
absolute pharmacokinetic parameters obtained in this
study, this approach provides an internally controlled
assessment of the relative distribution of these two agents.
In fact, in replicate measurements, the ratio of the biolog-
ical concentrations of the two compounds is more precise
than their individual concentrations (compare Additional
File 1 items S7 to S10). These data indicate the levels of
PCI-2050 and PCI-2022 in A549 xenograft tumors wereMolecular Cancer 2007, 6:9 http://www.molecular-cancer.com/content/6/1/9
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similar after all times intervals examined (30 minutes to
48 hours), consistent with similar levels of tumor growth
inhibition for the two agents. On the other hand, after
early time intervals, the ratio of PCI-2050 to PCI-2022 was
higher in kidney, the presumed organ of toxicity, based on
histological studies (data not shown). These findings lead
us to suggest distribution as a possible explanation for the
improved tolerance of PCI-2022 relative to PCI-2050.
Conclusion
Sapphyrins inhibit the proliferation of adherent cancer
cell lines in vitro at relatively low doses, leading to cell
death within a few days. Treatment A549 cells with sap-
phyrin PCI-2050 elicits the formation of ROS and results
in wide-spread decreases in transcript levels within four
hours. This inhibition is accompanied by a dosage-
dependent induction of RNA processing and transport,
transcriptional repressor, and chromatin remodeling
genes. These gene expression profiles dramatically differ
from those associated with other anticancer agents, such
as motexafin gadolinium, that induce oxidative stress in
cancer cells. In our in vivo studies, mice better tolerated
water-soluble sapphyrin analogues bearing multiple
hydroxyl groups relative to those with amphipathic func-
tionalities. Sapphyrin PCI-2022 inhibited A549 tumor
growth significantly in a xenograft model using a reason-
ably well tolerated dosing regimen. Thus, hydrophilic sap-
phyrin analogues display promise as investigational new
drug candidates for the treatment of solid tumors.
Methods
Cells and cell culture reagents
A549 lung and PC3 prostate cancer cell lines were pur-
chased from the American Type Culture Collection.
Unless otherwise indicated, all cell culture reagents were
purchased from Invitrogen (Carlsbad, CA). Cells were cul-
tured in a 5% CO2 incubator at 37°C in RPMI 1640
medium supplemented with 20 mM HEPES, 2 mM L-
glutamine, 10% fetal bovine serum (Biomeda, Foster City,
CA) and antibiotics (200 U/mL penicillin and 200 µg/mL
streptomycin) as previously described [26]. Cisplatin
(Sigma Chemical) was formulated in 0.9% saline and
stored at -20°C prior to use.
Cell viability
Cell viability was determined by using propidium iodide
(PI) flow cytometric analysis. A549 cells (2.5 × 105 cells
per plate) were seeded in 10 cm plates and allowed to
adhere overnight prior to treatment with sapphyrins or
actinomycin D. After 24 hours, the drug-containing
medium was removed, fresh medium was added, and the
cultures were allowed to grow an additional 48 hours. To
harvest, cells were washed with phosphate buffered saline
(PBS), and treated with 0.025% trypsin/EDTA for 10 min-
utes. Complete medium was then added and the cells iso-
lated by centrifugation. Cells present in the growth
medium and wash solution were isolated by centrifuga-
tion and included in the analysis. Cells were re-suspended
in 1 mL 10% bovine serum albumin (BSA) in PBS, an aliq-
uot of 3 × 105 cells transferred to a 4 mL tube, and the cells
isolated by centrifugation. Cell pellets were re-suspended
in 10% BSA in PBS supplemented with 2 µg/mL propid-
ium iodide (Sigma), incubated for 5 minutes at ambient
temperature, and subjected to flow cytometric analysis.
Flow cytometry was performed on a FACSCalibur instru-
ment and data were analyzed using the CellQuest Pro
software package (BD Biosciences).
Cell proliferation
The proliferation of exponential phase cultures of A549
and PC3 cells was assessed by tetrazolium salt reduction
[28]. In brief, A549 (2000 cells/well) or PC3 (4000 cells/
well) cells were seeded on 96-well microtiter plates and
allowed to adhere overnight. Stock solutions of sapphy-
rins or other inhibitors in medium were added by serial
dilution and plates were incubated at 37°C under a 5%
CO2/95% air atmosphere. After 24 hours, medium was
replaced with fresh medium. After 2 additional days,
medium was exchanged for fresh medium (150 µL/well)
supplemented with 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Sigma Chemical, 0.5
mg/mL). Plates were incubated at 37°C for two hours and
viable cells measured as described [26].
Measurement of reactive oxygen species
Reactive oxygen species (ROS) were measured in live cells
as intracellular peroxides by monitoring the oxidation of
2',7'-dichlorofluorescin-diacetate (DCFA) to 2',7'-dichlo-
rofluorescein (DCF) (Invitrogen). Cultures were harvested
as described above. Cells (1 × 106 per mL) were incubated
in a solution of 1 µg per mL DCFA in 0.5% BSA in HBSS
for 15 minutes at 37°C. Two mL additional 0.5% BSA in
HBSS was added, cells were isolated by centrifugation,
and the pellet re-suspended in a solution of 50 µg/mL 7-
aminoactinomycin D (7-AAD) in 0.5% BSA in HBSS. Cell
suspensions were incubated at ambient temperature for 2
to 3 minutes, and stored on ice until analysis. The fluores-
cent intensity in live (i.e., 7-AAD impermeable) cells was
analyzed by flow cytometry as described [27].
Measurement of DNA synthesis
Exponential phase A549 cultures were treated with con-
trol 5% mannitol vehicle or sapphyrin PCI-2050 for 4, 8,
or 31 hours. Thirty minutes prior to harvest, cultures were
treated with 5-bromo-2'-deoxyuridine (BrdU) at a final
concentration of 10 µM. Cells were isolated as described
above, washed once with 0.5% BSA in PBS, and the result-
ing cell pellets fixed using 0.5 mL Cytofix/Cytoperm rea-
gent (BD Biosciences). After incubation at ambient
temperature for 30 minutes, cells were isolated by centrif-Molecular Cancer 2007, 6:9 http://www.molecular-cancer.com/content/6/1/9
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ugation, washed with 3% FBS in PBS, re-suspended in
10% DMSO in medium, and stored at -20°C until analy-
sis. Cells were stained using a fluorescein-conjugated anti-
BrdU antibody (clone PRB1, E-Bioscience, San Diego, CA)
and 7-AAD. Cell cycle occupancy was analyzed by flow
cytometry using fluorescein signal as a measure of DNA
synthesis and 7-AAD signal as a measure of DNA content
as described [29]. For comparison, cultures were treated
with actinomycin D (200 ng/mL).
National Cancer Institute cell line screen
Testing of PCI-2050 in the NCI Developmental Therapeu-
tics Program panel of 60 human tumor cell lines yielded
an overall log value of drug concentration leading to 50%
growth inhibition (Log GI50) of -7.04 with a range of 2.34
(Additional File 1). Log GI50 was determined after 48
hours treatment using the sulforhodamine B assay. Indi-
vidual cell line values of Log GI50 were uploaded manually
into the COMPARE program website [30] to generate a
seed data set. This was analyzed using the COMPARE
algorithm [13] for correlation with mean graph patterns
of compounds (over 40,000) present in the synthetic
compound database. Analysis was performed using
default program parameters.
Gene expression profiling
A549 human lung cancer cells (1 × 105 cells per T-25 flask
in 7 mL complete RPMI 1640 medium) were seeded eight
days prior to treatment of non-cycling plateau phase cul-
tures with drug. At four hours prior to RNA isolation, sap-
phyrin PCI-2050 (1.25 or 2.5 µM final concentration),
actinomycin D (5 µg/mL final concentration), or control
(5% mannitol) solution was added to the cultures. Each
experiment was performed in triplicate. After incubation,
all cultures were washed twice with HBSS supplemented
with 0.5% BSA and total RNA was isolated and subjected
to analysis on Human Genome U133 Plus 2.0 Arrays
(Affymetrix, Santa Clara, CA), as described [31]. ArrayAs-
sist software (Stratagene/Affymetrix) and the RMA
(Robust Microarray Analysis) algorithm were used to gen-
erate scaled gene expression values. Genes at least 1.5-fold
differentially expressed in drug-treated relative to control
samples with a Benjamini-Hochberg corrected Student's t-
test p = 0.01 are reported. GeneOntology analyses were
conducted using WebGestalt software [32,33]. All scaled
fluorescent intensity values and .cel files are available at
the National Center for Biotechnology Information
(NCBI) Gene Expression Omnibus (GEO) repository [34]
under Series Accession Number GSE6400. In addition, all
scaled fluorescent intensity values are available in Addi-
tional File 2.
Mouse xenograft model
Animal care was in accordance with NIH and institutional
guidelines. For the A549 xenograft model [35], 1.25 × 106
A549 cells were injected subcutaneously/intramuscularly
into the right hind flank of 6 week old CD-1 nude mice
that had been irradiated with 4 Gy of total body irradia-
tion from a 137Cs radiation source one day prior to tumor
implantation. When the average size of tumors reached
approximately 100 mm3, mice were randomized by
tumor size to treatment groups containing 6 mice per
group. Mice were treated intravenously with 2 doses of
sapphyrin, 10 or 20 µmol/kg, on consecutive days. Vehi-
cle control treated animals received 5% mannitol on the
same schedule. Tumor and body weight measurements
were performed three times per week. Tumor volume was
calculated using the equation V (mm3) = a × b2/2, where
a is the largest diameter and b is the smallest diameter.
Data shown represent the mean ± standard error of mean
(± SEM). Body weight loss was less than 5% for all com-
pounds tested. One-way ANOVA on log transformed data
was performed using GraphPad Prism (GraphPad Soft-
ware Inc., San Diego, CA). P-values were corrected for
multiple comparisons to control using Dunnett's test.
Pharmacokinetic measurements
Female A549 tumor-bearing CD1 nude mice were pre-
pared as described above. When the average size of tumors
reached approximately 500 mm3, mice were randomly
assigned to study groups according to their tumor volume
on day 1 and then administered a single intravenous
injection of control vehicle (pre-dose) or a mixture of two
sapphyrins (5 µmol/kg PCI-2022 and 5 µmol/kg PCI-
2050 for a total sapphyrin dose of 10 µmol/kg). Blood
samples for pharmacokinetic analysis were obtained by
cardiac puncture into lithium heparin at the following
time points: 0 (pre-dose), 0.5, 1, 2, 4, 8, 24, and 48 hours
post injection. The plasma was separated by centrifuga-
tion and stored frozen until analysis.
Tumor and kidney were collected from each animal
immediately following the euthanasia procedure to eval-
uate the biodistribution of the compound. Plasma and
selected tissue samples were analyzed for PCI-2022 and
PCI-2050 using an HPLC method with fluorescence detec-
tion as described in the Additional File 1.
Competing interests
The following relationships could be construed as result-
ing in an actual, potential, or apparent conflict of interest
with regard to the manuscript submitted for review: Sev-
eral authors are employees of Pharmacylics, Inc., the com-
pany that is developing sapphyrins. Moreover, the Hacia
and Sessler laboratories have received research support
from Pharmacyclics.
Authors' contributions
ZW, CC, and D-G C contributed to compound design,
synthesis, and/or characterization. PSL performed flowMolecular Cancer 2007, 6:9 http://www.molecular-cancer.com/content/6/1/9
Page 11 of 12
(page number not for citation purposes)
cytometry analyses and obtained samples for microarray
analysis. PT and QF designed tumor growth studies and/
or toxicity studies. XM performed tumor growth studies
and toxicity studies. DT and DM designed bioanalytical
methods and/or pharmacokinetic experiments. LN
obtained NCI60 cell line data and contributed to writing
the manuscript. RAM contributed to writing the manu-
script. DMagda performed cellular proliferation assays,
contributed to designing compounds, experiments, and
writing the manuscript. JLS contributed to compound
design and writing the manuscript. BLP, SMY, and MWK
acquired and analyzed gene expression data. JGH contrib-
uted to designing experiments, writing the manuscript,
and conducting the gene expression data analyses.
Additional material
Acknowledgements
This research was supported in part by the Robert E. and May R. Wright 
Foundation (J.G.H.) and NIGMS GM58907 (J.L.S.).
References
1. Bauer VJ, Clive DLJ, Dolphin D, Paine JB III, Harris FL, King MM, Loder
J, Wang SWC, Woodward RB: Sapphyrins:  Novel Aromatic
Pentapyrrolic Macrocycles.  j am chem soc 1983, 105:6429-6436.
2. Broadhurst MJ, Grigg R, Johnson AW: Synthesis of 22-Pi-Electron
Macrocycles, Sapphyrins and Related Compounds.  J Chem
Soc, Perkin Trans 1972, 1:2111-2116.
3. Sessler J, Cyr MJ, Lynch V, McGhee E, Ibers JA: Synthetic and
Structural Studies of Sapphyrin, a 22-Pi-Electron Pentapyr-
rolic "Expanded Porphyrin".  j am chem soc 1990, 112:2810-2813.
4. Sessler JL, Davis JM: Sapphyrins: versatile anion binding agents.
Acc Chem Res 2001, 34:989-997.
5. Springs SL, Gosztola D, Wasielewski M, Kral V, Andreivsky A, Sessler
JL: Picosecond Dynamics of Energy Transfer in Porphyrin-
Sapphyrin Noncovalent Assemblies.  j am chem soc 1999,
121:2281-2289.
6. Judy MM, Matthews JL, Newman JT, Skiles HL, Boriack RL, Sessler JL,
Cyr M, Maiya BG, Nichol ST: In vitro photodynamic inactivation
of herpes simplex virus with sapphyrins: 22 pi-electron por-
phyrin-like macrocycles.  Photochem Photobiol 1991, 53:101-107.
7. Maiya BG, Cyr M, Harriman A, Sessler JL: Photodynamic Activity
of Diprotonated Sapphyrin:  A 22-Pi-Electron Pentapyrrolic
Porphyrin-like Macrocycle.  j phys chem 1990:3597-3601.
8. Kral V, Davis J, Andrievsky A, Kralova J, Synytsya A, Pouckova P, Ses-
sler JL: Synthesis and biolocalization of water-soluble sapphy-
rins.  J Med Chem 2002, 45:1073-1078.
9. Kral V, Brucker EA, Hemmi G, Sessler JL, Kralova J, Bose H Jr.: A
non-ionic water-soluble pentaphyrin derivative. Synthesis
and cytotoxicity.  Bioorg Med Chem 1995, 3:573-578.
10. Naumovski L, Ramos J, Sirisawad M, Chen J, Thiemann P, Lecane P,
Magda D, Wang Z, Cortez C, Boswell G, Gyu CD, Sessler J, Miller R:
Sapphyrins induce apoptosis in hematopoietic tumor-
derived cell lines and show in vivo antitumor activity.  Mol
Cancer Ther 2005, 4:968-976.
11. Naumovski L, Sirisawad M, Leca ne P, Chen J, Ramos J, Wang Z,
Cortez C, Magda D, Thiemann P, Boswell G, Miles D, Cho DG, Ses-
sler JL, Miller R: Tumor localization and antitumor efficacy of
novel sapphyrin compounds.  Mol Cancer Ther 2006, 5:2798-2805.
12. Rosenkranz AR, Schmaldienst S, Stuhlmeier KM, Chen W, Knapp W,
Zlabinger GJ: A microplate assay for the detection of oxidative
products using 2',7'-dichlorofluorescin-diacetate.  J Immunol
Methods 1992, 156:39-45.
13. Zaharevitz DW, Holbeck SL, Bowerman C, Svetlik PA: COMPARE:
a web accessible tool for investigating mechanisms of cell
growth inhibition.  J Mol Graph Model 2002, 20:297-303.
14. Chan J, Khan SN, Harvey I, Merrick W, Pelletier J: Eukaryotic pro-
tein synthesis inhibitors identified by comparison of cytotox-
icity profiles.  RNA 2004, 10:528-543.
15. Zalacain M, Zaera E, Vazquez D, Jimenez A: The mode of action of
the antitumor drug bouvardin, an inhibitor of protein syn-
thesis in eukaryotic cells.  FEBS Lett 1982, 148:95-97.
16. Simonova VS, Samusenko AV, Filippova NA, Tevyashova AN, Lyniv
LS, Kulik GI, Chekhun VF, Shtil AA: Olivomycin induces tumor
cell apoptosis and suppresses p53-induced transcription.  Bull
Exp Biol Med 2005, 139:455-459.
17. Yang E, van Nimwegen E, Zavolan M, Rajewsky N, Schroeder M, Mag-
nasco M, Darnell JE Jr.: Decay rates of human mRNAs: correla-
tion with functional characteristics and sequence attributes.
Genome Res 2003, 13:1863-1872.
18. Umehara H, Nishii Y, Morishima M, Kakehi Y, Kioka N, Amachi T,
Koizumi J, Hagiwara M, Ueda K: Effect of cisplatin treatment on
speckled distribution of a serine/arginine-rich nuclear pro-
tein CROP/Luc7A.  Biochem Biophys Res Commun 2003,
301:324-329.
19. Brend N: Inhibition of bleomycin lung toxicity by n-acetyl
cysteine in the rat.  Pathology 1985, 17:108-110.
20. Sinha BK, Mimnaugh EG, Rajagopalan S, Myers CE: Adriamycin acti-
vation and oxygen free radical formation in human breast
tumor cells: protective role of glutathione peroxidase in
adriamycin resistance.  Cancer Res 1989, 49:3844-3848.
21. Chen H, Liu X, Patel DJ: DNA bending and unwinding associ-
ated with actinomycin D antibiotics bound to partially over-
lapping sites on DNA.  J Mol Biol 1996, 258:457-479.
22. Radhakrishnan SK, Gartel AL: A novel transcriptional inhibitor
induces apoptosis in tumor cells and exhibits antiangiogenic
activity.  Cancer Res 2006, 66:3264-3270.
Additional file 1
Methods and statistical analyses used in these studies. Here we provide 
Gene Ontology (GO) analyses, the protocol for tissue extraction method-
ology and supplemental biodistribution analyses, details concerning the 
synthesis of hydrophilic sapphyrins, and NCI Developmental Therapeutics 
Program tumor cell line panel data
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-6-9-S1.doc]
Additional file 2
Normalized hybridization signal intensity values for all microarray exper-
iments. This file provides all the processed hybridization signals generated 
in gene expression profiling experiments along with statistical analyses of 
differentially expressed genes.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-6-9-S2.txt]
Additional file 3
Selected gene expression data Part I. Data from all 94 probe tilings show-
ing up-regulation in response to 1.25uM sapphyrin PCI-2050 and down-
regulation in response to 5ug/mL actinomycin D
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-6-9-S3.xls]
Additional file 4
Selected gene expression data Part II. Probe tilings up-regulated by both 
doses of PCI-2050 but down-regulated by actinomycin D.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-6-9-S4.xls]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Molecular Cancer 2007, 6:9 http://www.molecular-cancer.com/content/6/1/9
Page 12 of 12
(page number not for citation purposes)
23. Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM,
Averett LM, Zhao H, Davis RE, Sathyamoorthy M, Wahl LM, Harris
ED, Mikovits JA, Monks AP, Hollingshead MG, Sausville EA, Staudt LM:
Genomic-scale measurement of mRNA turnover and the
mechanisms of action of the anti-cancer drug flavopiridol.
Genome Biol 2001, 2:RESEARCH0041.
24. Khobta A, Ferri F, Lotito L, Montecucco A, Rossi R, Capranico G:
Early effects of topoisomerase I inhibition on RNA polymer-
ase II along transcribed genes in human cells.  J Mol Biol 2006,
357:127-138.
25. Carson JP, Zhang N, Frampton GM, Gerry NP, Lenburg ME, Christ-
man MF: Pharmacogenomic identification of targets for adju-
vant therapy with the topoisomerase poison camptothecin.
Cancer Res 2004, 64:2096-2104.
26. Magda D, Lecane P, Miller RA, Lepp C, Miles D, Mesfin M, Biaglow JE,
Ho VV, Chawannakul D, Nagpal S, Karaman MW, Hacia JG: Motex-
afin gadolinium disrupts zinc metabolism in human cancer
cell lines.  Cancer Res 2005, 65:3837-3845.
27. Lecane PS, Karaman MW, Sirisawad M, Naumovski L, Miller RA, Hacia
JG, Magda D: Motexafin gadolinium and zinc induce oxidative
stress responses and apoptosis in B-cell lymphoma lines.  Can-
cer Res 2005, 65:11676-11688.
28. Mosmann T: Rapid colorimetric assay for cellular growth and
survival: application to proliferation and cytotoxicity assays.
J Immunol Methods 1983, 65:55-63.
29. Gratzner HG, Leif RC: An immunofluorescence method for
monitoring DNA synthesis by flow cytometry.  Cytometry 1981,
1:385-393.
30. COMPARE program website [http://dtp.nci.nih.gov/docs/
compare/compare.html ].  .
31. Karaman MW, Houck ML, Chemnick LG, Nagpal S, Chawannakul D,
Sudano D, Pike BL, Ho VV, Ryder OA, Hacia JG: Comparative anal-
ysis of gene-expression patterns in human and African great
ape cultured fibroblasts.  Genome Res 2003, 13:1619-30.
32. WebGestalt software [http://bioinfo.vanderbilt.edu/webge-
stalt/ ].  .
33. Zhang B, Kirov S, Snoddy J: WebGestalt: an integrated system
for exploring gene sets in various biological contexts.  Nucleic
Acids Res 2005, 33:W741-W748.
34. NCBI Gene Expression Omnibus repository [http://
www.ncbi.nlm.nih.gov/geo/ ].  .
35. Nishizaki M, Meyn RE, Levy LB, Atkinson EN, White RA, Roth JA, Ji
L: Synergistic inhibition of human lung cancer cell growth by
adenovirus-mediated wild-type p53 gene transfer in combi-
nation with docetaxel and radiation therapeutics in vitro and
in vivo.  Clin Cancer Res 2001, 7:2887-2897.